APR 26, 2017 09:00 AM PDT

WEBINAR: Reliable Detection of Low Abundance Somatic Mutations from Heterogeneous Solid Tumor Samples

SPONSORED BY: Agena Bioscience
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Medical Director, Molecular Pathology, Blood Bank and Blood Donor Services The Medical Foundation
      Dr. Sutton received her M.D. and Ph.D. from Indiana University, followed by anatomic and clinical pathology residency at Bowman Gray School of Medicine at Wake Forest University in Winston-Salem, NC, and an additional year of surgical pathology training at Medical University of South Carolina in Charleston, SC. She completed a fellowship in Molecular Genetic Pathology at University of Oklahoma Health Sciences Center in 2007. In addition to anatomic and clinical pathology she is board certified in Blood Banking and Transfusion Medicine, and Molecular Genetic Pathology. She joined The Medical Foundation in 2000 and serves as Medical Director of Blood Donor Services, Blood Bank Services and Molecular Pathology. Dr. Sutton received the 2015 Hope Award from the American Cancer Society for her work in solid tumor molecular diagnostics, and the 2016 Victor Muller Achievement Award from the Indiana State Association of Blood Banks for her commitment to education, science, patient care and community service in the field of blood banking and transfusion medicine.
    • Senior Director, Applications Development Agena Bioscience
        Darryl Irwin has been leading the Scientific Services and Applications Development operations at Agena Bioscience (and its predecessor Sequenom Inc.) in Asia Pacific, and more recently in a global capacity, for 9 years. Previously, Darryl led the genotyping division at the Australian Genome Research Facility. Darryl has also held positions at the Mater Laboratory Services, a hospital-based clinical genetics laboratory and Agen Biomedical, an immuno-diagnostics manufacturer. Darryl has a PhD from the University of Queensland in Non-Invasive Prenatal Testing (NIPT) and a BSc in Biotechnology from the Queensland University of Technology. Darryl has authored more than 20 publications, numerous book chapters, and holds several patents.


      DATE: April 26, 2017
      TIME: 9:00AM PT, 12:00PM ET

      Biopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with limited tumor content in a large background of normal or wild type cells. Current mutation testing platforms offer a wide range of analytical sensitivity. Despite considerable progress, analytical challenges remain to be resolved, such as the need for reliable detection of low abundance somatic mutations, particularly in small specimens with a low percentage of tumor cells. 
      In this webinar, Dr. Darryl Irwin from Agena Bioscience will present the recent advances which enable a limit of detection of 1% using iPLEX® HS chemistry on the MassARRAY® System. iPLEX HS chemistry is uniquely suited for the detection of low frequency mutations from highly fragmented and low quality specimens from FFPE, FNA, and cytology smears. 
      Dr. Bobbie Sutton from The Medical Foundation will share results from two recent clinical research studies, both of which utilized iPLEX HS Panels targeted for the detection of low abundance mutations from pulmonary and colorectal adenocarcinoma.

      Learning Objectives:

      • Understand both the need for detecting low abundance mutations and the challenges of working with heterogeneous solid tumor samples
      • Learn how the iPLEX® HS Chemistry enables detection of mutations as low as 1% allele frequency from heterogeneous solid tumor samples

      Show Resources